Neumann Discusses Cures Act and New FDA Draft Guidance on Communication
In his latest Health Affairs blog posting, PHE Scientific Advisor Peter Neumann and co-author Elle Pope examine Section 3037 of the Cures Act and new FDA draft guidance, which indicate that drug companies will have expanded flexibility to communicate proactively with payors and formulary committees about the real-world impacts of their products.
To read Dr. Neumann’s blog, please click here.
Live Webinar: How can we quantify the long-term health and economic impacts of treatments to society?
Please join us for our upcoming 1-hour live webinar on Thursday, October 25th at 11 :00 AM PT /2:00 PM ET.Projecting Long-term Societal Value: The Health Economics Medical lnnovation Simulation (THEMIS) will be presented by PHE Founder and Scientific Advisor Dana Goldman, PhD, and PHE Director of Policy and Economics, Alison Ward, PhD.REGISTER NOW